about
AIDS vaccine: efficacy, safety and ethics.Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission.Simple criterion for selection of flavonoid compounds with anti-HIV activity.Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control.Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor.Physical activity and natural anti-VIP antibodies: potential role in breast and prostate cancer therapy.New in silico and conventional in vitro approaches to advance HIV drug discovery and design.Discovery of new therapeutic targets by the informational spectrum method.The role of long-range intermolecular interactions in discovery of new drugs.Assessment of hepatitis C virus protein sequences with regard to interferon/ribavirin combination therapy response in patients with HCV genotype 1b.Aerobic exercise training as a potential source of natural antibodies protective against human immunodeficiency virus-1.A bioinformatics approach to identify natural autoantibodies from healthy blood donors' sera reactive with the HCV NS5A-derived peptide by immunoassay.Can natural antibodies to VIP or VIP-like HIV-1 glycoprotein facilitate prevention and supportive treatment of breast cancer?Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular diseaseApolipoprotein e gene polymorphism as a risk factor for ischemic cerebrovascular diseaseAngiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian populationAssociation of lipoprotein lipase gene Asn291Ser DNA polymorphism with plasma lipid levels and blood pressure levels in healthy population of SerbiaSynthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets
P50
Q30366863-E51A7E5E-FBAA-4CC6-AB4E-41ED8F04FCF3Q30430279-6C1D35E8-1946-4425-8BC1-A8A5B7C255E4Q33267641-5A9E0007-5E3E-4E3B-981B-BCD190CCFE05Q33427655-3C11DFC9-6449-4EB9-8792-270E722A6E7FQ33507177-E3E62767-6C22-456A-9638-FA1127B05874Q34091473-3470D7B9-382C-4D0D-B297-AEB53280E94EQ34483539-8734F65B-59DC-47B9-B48E-B4C96BD23A61Q37294351-2106E0AE-DEA3-4ACB-B70B-A974DA9F9BA8Q38014574-AF980FA7-C349-4327-95A5-6A5826BAD96EQ43047642-3D4D6262-9AB5-4412-9AF0-8B3B0B33A8BFQ45383501-9C654316-03F0-492D-BC4F-D72945285767Q48145319-C0331BD4-70DB-4722-AFC3-AFFC8E88E077Q57015026-E5E026EC-BF0F-4C7A-BFE7-E061EC3450C1Q57015034-D392C8A8-8784-4421-B8AC-EB50520696ECQ57015040-C06C3A3A-CE19-430E-A98D-D56174AA612AQ57015044-93F87917-93EA-4284-ADA0-CE96E11CCF54Q57015047-950C36B0-640D-402B-910E-8B41AFBC2FD4Q64086176-6C17D8A7-422A-4216-A4A9-928DA64E4C11
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sanja Glisic
@ast
Sanja Glisic
@en
Sanja Glisic
@es
Sanja Glisic
@nl
Sanja Glisic
@sl
type
label
Sanja Glisic
@ast
Sanja Glisic
@en
Sanja Glisic
@es
Sanja Glisic
@nl
Sanja Glisic
@sl
prefLabel
Sanja Glisic
@ast
Sanja Glisic
@en
Sanja Glisic
@es
Sanja Glisic
@nl
Sanja Glisic
@sl
P106
P1153
7005776793
P31
P496
0000-0001-5691-1055